Literature DB >> 22209696

Changing incidence and clinical manifestations of Clostridium difficile-associated diarrhea detected by combination of glutamate dehydrogenase and toxin assay in Northern Taiwan.

Yi-Chieh Lee1, Jann-Tay Wang, An-Chi Chen, Wang-Huei Sheng, Shan-Chwen Chang, Yee-Chun Chen.   

Abstract

BACKGROUND/
PURPOSE: The incidence of Clostridium difficile-associated diarrhea (CDAD) is increasing worldwide. Spread of an epidemic hypervirulent strain in southern Taiwan was associated with poor outcome. This prospective study evaluates the incidence and clinical manifestation of CDAD following a hospital-wide hand hygiene promotion program in a 2,200-bed teaching hospital in northern Taiwan. PATIENTS AND METHODS: From June 1, 2010 to October 31, 2010, a predefined protocol was used to actively survey CDAD at 11 high-risk units. Stool samples of patients with antibiotic-associated diarrhea (AAD) were submitted for stool culture and toxin A/B assay using a combined enzyme immunoassay. CDAD was diagnosed by a positive toxin assay.
RESULTS: The incidence of CDAD was 0.45/1000 patient-days and was highest in medical intensive care units (7.9/1000 patient-days), followed by hemato-oncology wards, and infectious disease wards. Occurrence of CDAD was associated with ≥3 stool pus cells per high power field (p = 0.018), prior use of metronidazole (p = 0.029), high usage of beta-lactamase stable penicillins (p = 0.046), and anaerobe-active antibiotics (p = 0.029). No attributable mortality was found. The incidence of CDAD was lower than that previously observed (1.0/1000 patient-days in 2003, p < 0.001).
CONCLUSION: This study showed a lower incidence of CDAD and absence of attributable mortality. The impact of hand hygiene promotion and other infection control measures on decreasing incidence of CDAD warrants further elucidation.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209696     DOI: 10.1016/j.jmii.2011.12.001

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  11 in total

1.  Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.

Authors:  Chun-Hsing Liao; Wen-Chien Ko; Jang-Jih Lu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

2.  Fecal microbiota transplantation in relapsing Clostridium difficile infection.

Authors:  Faith Rohlke; Neil Stollman
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

3.  Epidemiology of Clostridium difficile infection: results of a hospital-based study in Krakow, Poland.

Authors:  J Czepiel; J Kędzierska; G Biesiada; M Birczyńska; W Perucki; P Nowak; A Garlicki
Journal:  Epidemiol Infect       Date:  2015-04-10       Impact factor: 4.434

4.  Risk factors for recurrent hospital-acquired Clostridium difficile infection in a Japanese university hospital.

Authors:  Mayu Hikone; Yusuke Ainoda; Sayaka Tago; Takahiro Fujita; Yuji Hirai; Kaori Takeuchi; Kyoichi Totsuka
Journal:  Clin Exp Gastroenterol       Date:  2015-07-14

5.  Molecular epidemiology of Clostridium difficile at a medical center in Taiwan: persistence of genetically clustering of A⁻B⁺ isolates and increase of A⁺B⁺ isolates.

Authors:  Ju-Hsin Chia; Hsin-Chih Lai; Lin-Hui Su; An-Jing Kuo; Tsu-Lan Wu
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

Review 6.  The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact.

Authors:  Nienke Z Borren; Shadi Ghadermarzi; Susan Hutfless; Ashwin N Ananthakrishnan
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

7.  Epidemiology of Clostridium difficile infection in Asia.

Authors:  Deirdre A Collins; Peter M Hawkey; Thomas V Riley
Journal:  Antimicrob Resist Infect Control       Date:  2013-07-01       Impact factor: 4.887

Review 8.  Efficacy and Safety of Metronidazole Monotherapy versus Vancomycin Monotherapy or Combination Therapy in Patients with Clostridium difficile Infection: A Systematic Review and Meta-Analysis.

Authors:  Rui Li; Laichun Lu; Yu Lin; Mingxia Wang; Xin Liu
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

9.  Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan.

Authors:  Yuan-Pin Hung; Pei-Jane Tsai; Yuan-Ti Lee; Hung-Jen Tang; Hsiao-Ju Lin; Hsiu-Chuan Liu; Jen-Chieh Lee; Bo-Yang Tsai; Po-Ren Hsueh; Wen-Chien Ko
Journal:  Infect Drug Resist       Date:  2018-08-15       Impact factor: 4.003

10.  Global burden of Clostridium difficile infections: a systematic review and meta-analysis.

Authors:  Evelyn Balsells; Ting Shi; Callum Leese; Iona Lyell; John Burrows; Camilla Wiuff; Harry Campbell; Moe H Kyaw; Harish Nair
Journal:  J Glob Health       Date:  2019-06       Impact factor: 4.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.